(2025). Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma. Blood and Lymphatic Cancer : Targets and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma."
Blood and Lymphatic Cancer : Targets and Therapy 2025.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma."
Blood and Lymphatic Cancer : Targets and Therapy, 2025.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.